Ja, es gab wieder gute News - aber die gibt es seit 6 Monaten in Serie!
3D Signatures hat erfreuliche Quartalszahlen fürs 3. Quartal (Geschäftsjahr geht jeweils von Okt. bis Sept.) bekanntgegeben, man machte nur einen Quartalsverlust von $ 0,04 und man hat erfreuliche 2,55 Mio. Cash!
Hier die Original-News in engl. Sprache:
3D SIGNATURES INC. REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS
3D Signatures Inc. has released its operational and financial results for its fiscal third quarter ended March 31, 2017.
Third quarter highlights:
On Jan. 4, 2017, 3D Signatures announced that its common shares had started trading on the OTCQB Venture Market and on the Frankfurt Stock Exchange under the symbols TDSGF and 3D0, respectively. The company also announced that it had secured Depository Trust Company eligibility for its common shares listed on the OTCQB.
On Jan. 6, 2017, the company announced the appointment of accomplished health care industry veteran Joost van der Mark as its chief business officer.
On Jan. 6, 2017, 3D Signatures announced the closing of the third and final tranche of a fully subscribed brokered private placement. The company issued a total of 597,082 units pursuant to the third tranche of the private placement, which were sold at 75 cents per unit for gross proceeds of $148,800, pursuant to the exercise of the agent's overallotment option.
On Jan. 9, 2017, the company announced that new data from a study published in Urologic Oncology suggested that the use of its proprietary TeloView technology platform may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined (hormonal) androgen deprivation therapy and radiation therapy.
On Jan. 18, 2017, the company announced that it had awarded 253,125 incentive stock options to its chief executive officer, Jason Flowerday, at an exercise price of 79 cents per share. The options are exercisable for a 10-year period from the date of grant (Jan. 17, 2017) and will vest in four tranches of 63,281 each, every six months from Oct. 1, 2017, to April 1, 2019.
On Feb. 15, 2017, 3D Signatures announced the appointment of medical diagnostics expert Harry Glorikian to its business advisory board.
On Feb. 21, 2017, 3D Signatures announced a presentation at the 24th International Molecular Medicine Tri-Conference in San Francisco, Calif., by its co-founder and principle inventor, Dr. Sabine Mai, on the results of a prospective blood-based prostate cancer pilot study using the TeloView software platform. Based on blinded blood samples, TeloView correctly predicted the stability and aggressiveness of disease for each of the study's 50 intermediate-risk prostate cancer patients.
On Feb. 23, 2017, the company announced the initiation of the validation program for its Hodgkin's lymphoma test, Telo-HL.
On March 14, 2017, 3D Signatures announced that it had made the final payment to CancerCare Manitoba (CCBM) for the purchase of intellectual property, all of which had been assigned from CCMB to 3D Signatures on June 26, 2014.
On March 21, 2017, the company announced clinical study results which confirm that, based on a swab from the inside of a patient's cheek, its proprietary TeloView software platform has the ability to identify patients with Alzheimer's disease and, furthermore, distinguish between mild, moderate and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer's Disease.
On March 29, 2017, 3D Signatures announced that it had successfully completed internal analytical assay validation for its Telo-HL test pursuant to FDA (Food and Drug Administration) guidelines. This process is referred to as stage 2 of the validation program as set out in the company's news release dated Feb. 23, 2017.
"The fiscal third quarter was another period of meaningful progress for 3DS, and builds on our accomplishments to both increase awareness of 3-D telomere analysis as a disruptive technology and to advance the TeloView platform toward commercialization," said Mr. Flowerday.
Summary of third quarter results
For the three months ended March 31, 2017, the company reported a net loss of $2,171,822 or four cents per common share, as compared with a net loss of $570,449 or two cents per common share for the three months ended March 31, 2016. The increase in net loss is primarily due to increases in salaries, wages, benefits and stock-based compensation as a result of the company's hiring of additional employees, as well as the appointment of a new business advisory board member, to support its global growth strategy. Additional increases in professional fees and investor relations costs are the result of 3D Signatures becoming a publicly traded company in September, 2016.
As at March 31, 2017, the company's cash amounted to $2,552,822.
|
Thread abonnieren
